NCT02451826Unknown1 期
A Randomized Study to Evaluate the Effect of a Contraceptive Vaginal Ring Delivering a Daily Dose of 2500 μg of Ulipristal Acetate Combined With a Single or Repeated Levonorgestrel 1.5mg Oral Dose on Inhibition of Ovulation, Endometrial Changes and Bleeding Patterns in Normal Cycling Women
Population Council1 个研究点 分布在 1 个国家目标入组 19 人开始时间: 2015年5月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 19
- 试验地点
- 1
- 主要终点
- Pharmacodynamic efficacy as measured by the effects of a vaginal ring delivering Ulipristal acetate consistently combined with levonorgestrel administration on the endometrium
研究概览
简要总结
The purpose of this study is to determine the effect of a contraceptive vaginal ring on inhibition of ovulation, endometrial changes and bleeding patterns in normal cycling women.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 35 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Not at risk for pregnancy based on one of the following: a. subject has undergone sterilization; b. subject is monogamous and her male partner has undergone sterilization
- •Have regular menstrual cycles of 25-35 days duration
- •Have an intact uterus and both ovaries
- •Will be able to comply with the protocol
- •Capable of giving informed consent
排除标准
- •Women participating in another clinical trial
- •Women not living in the catchment area of the clinic
- •Known hypersensitivity to progestins or antiprogestins
- •Known hypersensitivity to silicone rubber
- •Any chronic disease
- •All contraindications to oral contraceptive use, including: a. Thrombophlebitis or thromboembolic disorders; b. Past history of deep vein thrombophlebitis or thromboembolic disorders; c. Past or current cerebrovascular or coronary artery disease; d. Migraine with focal aura; e. Known or suspected carcinoma of the breast; f. Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia; g. Undiagnosed abnormal genital bleeding; h. Cholestatic jaundice of pregnancy or jaundice with prior pill use; i. Hepatic adenomas or carcinomas; j. Known or suspected pregnancy
- •Desire to get pregnant during the study (through the use of reproductive technology for sterilized women or vasectomy reversal for sterilized partners)
- •Breastfeeding
- •Undiagnosed vaginal discharge or vaginal lesions or abnormalities
- •Women with a current abnormal Pap: In accordance with the Bethesda system of classification: smear suggestive of high-grade pre-cancerous lesion(s), including HGSIL, are excluded; Women with LGSIL or ASCUS/high-risk HPV positive may participate if further evaluated with colposcopy and biopsy and no evidence of a lesion with a severity > CIN I is present and/or endocervical curettage is negative; Women with a biopsy finding of CIN I should have follow up for this finding per standard of care; women are excluded it treatment is indicated.
- •Known benign or malignant liver tumors; known active liver disease
- •Cancer (past history of any carcinoma or sarcoma)
- •Medically diagnosed severe depression currently or in the past
- •Known or suspected alcoholism or drug abuse
- •Abnormal serum fasting clinical chemistry values
- •Women with known abnormal thyroid status
- •Women with known impaired hypothalamic-pituitary-adrenal reserve
- •Average diastolic BP > 85 mm or systolic BP >135 mm Hg after 5-10 minutes rest
- •Body mass index (BMI) > 30.0 (or ≤18)
- •Smoking in women who will be 35 years during the course of the trial; women < 35 years who smoke greater than 15 cigarettes per day must be evaluated by the PI for inclusion based on risk factors that would increase their risk for CVD and thromboembolism, e.g. lipid levels, glucose level, BP, BMI, family history of CVD at a young age.
- •Women with severe cystoceles or rectoceles
- •Use within the past 2 months of any implanted hormonal contraceptives including Mirena [progestin containing intrauterine system (IUS)] or Norplant (subdermal implant delivering LNG). NOTE: Removal of implanted hormonal contraceptives must have been for personal reasons unrelated to the purpose of enrollment in this study.
- •Current use of a non-hormone containing IUD. NOTE: Removal of an IUD must have been for personal reasons unrelated to the purpose of enrollment in this study.
- •Use of injectable contraceptives during the previous 3 months (e.g. Cyclofem) or 6 months (e.g. DMPA).
- •Women who do not have at least two progesterone measurements during the control cycle of ≥10nmol/L will be excluded from further participation in the study (See Section 13.4.1)
研究组 & 干预措施
1.5 mg tablet LNG after 12 weeks
Active Comparator
CVR delivering 2,500 µg of Ulipristal acetate per day and a single dose of levonorgestrel delivered in a 1.5 mg tablet after 12 weeks of CVR use
干预措施: Ulipristal acetate (Drug)
1.5 mg tablet LNG every 4 weeks
Active Comparator
CVR delivering 2,500 µg of Ulipristal acetate per day and one 1.5 mg tablet levonorgestrel every 4 weeks of CVR use (three times).
干预措施: Ulipristal acetate (Drug)
结局指标
主要结局
Pharmacodynamic efficacy as measured by the effects of a vaginal ring delivering Ulipristal acetate consistently combined with levonorgestrel administration on the endometrium
时间窗: 3 months
Endometrial biopsies (EB) will be taken as follows, a.During the follicular phase (between Day 9 and Day 12) of the baseline/control cycle, b. At the end of the 14th week of treatment (14 days after the 12 week LNG administration and end of CVR use), c. During the follicular phase (between Day 9 and Day 12 of the second menstrual cycle after ring removal). Also, endometrial changes will be measured by histological examination, immunohistochemistry, and assessment of proliferation markers (Ki67, Phospho H3 and bcl2).
次要结局
- Safety as measured by number of participants with occurrence of adverse events (AEs) and concomitant medication use(3 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Functionality of Male Condoms With a Silicone Elastomer Vaginal RIngHuman Immunodeficiency VirusNCT01755741International Partnership for Microbicides, Inc.70
已完成
2 期
Assessment of a Vaginal Ring With Meloxicam in the Treatment of DysmenorrheaDysmenorrheaNCT02255045Laboratorios Andromaco S.A.68
已完成
4 期
Effects of a Vaginal Contraceptive Ring on Vaginal Microbiota and Local ImmunityBacterial VaginosisNCT02432404University of Washington81
已完成
不适用
An Intervention Delivered by App Instant Messaging to Increase the Acceptability of Effective Contraception Among Young People in TajikistanContraceptionNCT02905513London School of Hygiene and Tropical Medicine580
已完成
不适用
An Intervention Delivered by App Instant Messaging to Increase Use of Effective Contraception Among Young Women in BoliviaContraceptionNCT02905526London School of Hygiene and Tropical Medicine645